mandible, and trunk. All skin symptoms were confined to previously irradiated areas. After RRD was diagnosed by exclusion of other causes and skin biopsy, sorafenib was paused. With the administration of topical corticosteroids and oral antihistamines, the skin reaction subsided within several days. Sorafenib was readministered after 3 weeks, which did not lead to recurrence of RRD but did cause fluctuating fever. Discussion Only four other such cases have been reported in the literature and WHO pharmacovigilance database on individual case safety reports. The current report is the first to show a potential relationship between the severity of sorafenib-induced RRD and radiation dose, histopathological features, and simultaneous acute radiation dermatitis and mucositis. Conclusion RRD induced by sorafenib is a rare phenomenon, but should be considered in patients showing erythematous skin lesions 1-2 weeks after initiation of the drug, predominantly in areas where skin has been irradiated with an equivalent dose ≥ 30 Gy. Discontinuation of sorafenib with possible readministration should be evaluated with respect to the clinical situation and severity of reaction. 
dysesthesia (hand-foot reaction), alopecia, and rash [3] [4] [5] . Here we present a rare case of RRD induced by sorafenib in a patient irradiated for several bone metastases from HCC. A systematic review of published cases in the scientific literature and the WHO pharmacovigilance database was conducted to identify risk factors, signs, and course of this reaction, as well as outcome.
Case study
A 77-year-old male Caucasian (weight 67 kg; height 160 cm; body mass index, BMI 26 kg/m 2 ) with hepatitis C-associated HCC (diagnosed April 2014) received radiation to several metastatic bone sites between January and March 2015. Radiation dose was 20-36 Gy delivered in 5-12 fractions (Table 1) , which resulted in a good analgesic effect with improvement of the patient's mobility. Sorafenib was started at a dosage of 200 mg orally twice daily in mid-March, with slow dose increments. Long-term comedication included amlodipine, metoprolol, hydrochlorothiazide for hypertension, tamsulosin for prostatic hyperplasia, oxycodone for pain, and esomeprazole for gastric ulcer prophylaxis.
One week after initiation of sorafenib the patient presented with fever (38.2 °C), rising C-reactive protein (CRP; 23 mg/l), and a painless erythematous lesion at the right elbow where he had undergone surgery for pathologic fracture and received postoperative irradiation with 12 fractions of3 Gy. Blood pressure, heart rate, and oxygen saturation were unchanged compared to baseline values (blood pressure 150/80 mmHg; pulse rate 91/min; oxygen saturation, SpO 2 92 %). Assuming a local skin infection, antibiotics (1 g amoxicillin/200 mg clavulanic acid every 8 h i.v.) were started. As per schedule, the dose of sorafenib was escalated to 400 mg twice daily and the erythema spread proximally into a distinct rectangular shape equivalent to the previous irradiation field during the following days. In addition, other skin lesions evolved, all of them in currently (acute radiation dermatitis, ARD) or previously irradiated areas (RRD) ( Fig. 1 ; Table 1 ). RRD was suspected and sorafenib was stopped 1 week after the first symptoms occurred. Other affected skin areas included currently and previously irradiated areas such as the mandible, scapula, and spine. Multiple erythematous papules and plaques resulted in dermatitis grade 1-3 according to the Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 [6] . The severity of dermatitis showed a potential relationship with the administered radiation dose, because ≥ grade 2 skin toxicity predominantly occurred when the maximal skin dose was above 30 Gy ( Table 1 ). In addition, the patient developed urinary retention and severe mucositis CTCAE grade 2. Radiation recall dermatitis (RRD) is defined as an acute inflammatory reaction confined to previously irradiated skin after the administration of certain drugs, mostly classical chemotherapeutics, usually occurring months or even years after radiotherapy [1] .
Sorafenib is an oral multikinase inhibitor and targeted anticancer substance. Sorafenib is indicated for treatment of unresectable hepatocellular carcinoma (HCC), advanced 133 I-refractory thyroid carcinoma, or advanced pretreated renal cell carcinoma [2] . The most common adverse effects of sorafenib are gastrointestinal, with abdominal pain, diarrhea, and nausea; hepatic, with elevated levels of liver enzymes; and dermatologic, with palmar-plantar erythro-reported after treatment of gliomas [15, 16] , pancreatic cancer [17, 18] , or sarcoma [19] [20] [21] .
We performed a systematic search for RRD induced by sorafenib in MEDLINE ("radiation recall dermatitis sorafenib"; "recall sorafenib") and the WHO global database "VigiBase ® " on pharmacovigilance [22] . So far, only three cases have been reported in the literature (Table 2) . Hsieh et al. described RRD in a patient with HCC after intensity-modulated radiotherapy (IMRT) of the liver with 48 Gy and start of sorafenib 300 mg twice daily 10 days after SBRT. A well-defined skin lesion on the right upper abdomen appeared 1 week after the start of sorafenib and resolved 10 days after stopping the drug and local therapy with clobetasol propionate [23] . Oh and colleagues observed an erythematous lesion with dry desquamation on the right chest wall in a patient with HCC irradiated for a chest wall mass with 39 Gy. After completion of radiotherapy, sorafenib was started with 400 mg twice daily and the skin lesion occurred after 14 days. Another 10 days later, the patient presented with a disseminated exanthematous rash and severe pruritus. Sorafenib was stopped and an oral antihistamine was prescribed. One week later, the symptoms resolved and sorafenib was restarted without any further skin reactions [24] . Chung et al. presented the case of a 38-year-old male with liver metastases treated with palliative radiotherapy (6fractions of 5 Gy). Sorafenib was started with 200 mg twice daily 3 weeks after completion of radiotherapy. Several days later, the patient presented with pruritus of the left posterior flank, hyperpigmentation, and dry desquamation in the previously irradiated areas. Sorafenib 200 mg twice daily was continued and a topical steroid cream was administered. The pruritus and skin reaction resolved 2-3 weeks later. The dose of sorafenib was escalated to 400 mg twice daily. No further exacerbations of the RRD occurred [25] . In the pharmacovigilance mines (fexofenadine 180 mg twice daily) was administered. Blood cultures remained negative. The patient developed a generalized eczematous skin reaction with severe pruritus. Skin biopsy of an erythematous lesion located on the right chest revealed diffuse perivascular lymphohistiocytic infiltrate with few eosinophils in the corium, and apoptotic keratinocytes and distinct vacuolization in the junction zone (Fig. 2) .
The skin reaction decreased within 14 days after termination of sorafenib. After an interval of 3 weeks, sorafenib was restarted at a reduced dosage of 200 mg twice daily. The skin reaction did not worsen, but the patient developed fluctuating fever, so sorafenib was eventually discontinued after another week.
Systematic review and discussion
We present a case of increased skin toxicity and severe mucositis shortly after initiation of sorafenib, with worsening ARD in areas currently under treatment (acetabulum, SIJ, L1, mandible), and RRD in previously irradiated areas (scapula, humerus, T3, T6, T10, 8th rib; see Table 1 ).
The radiosensitizing effect of sorafenib in combination with radiotherapy has been shown in different cell lines [7] [8] [9] [10] [11] . Peters et al. reported on a patient receiving sorafenib and irradiation for lumbar metastasis of a renal cell carcinoma who died of severe bowel complications after radiotherapy [12] .
In contrast to other cutaneous complications of molecularly targeted therapies, such as hand-foot skin reaction, RRD induced by sorafenib is a rare phenomenon. In large clinical trials in patients with HCC who received sorafenib in combination with radiotherapy, cases of RRD were not reported [13, 14] . Similarly, no known reactions have been [6] , RT radiotherapy, EQD2 Equivalent dose in 2-Gy fractions, L lumbar vertebra, l left, r right, RA rapid arc, SIJ sacroiliac joint, T thoracic vertebra, 3D three-dimensional conformal radiotherapy, PTV planning target volume a postoperative radiotherapy database, only one other case of "recall phenomenon" and sorafenib was identified. Sorafenib was the only suspected drug in a 51-year-old male with metastatic renal cell carcinoma. Other reported symptoms included vesicular rash, swelling, tenderness, and pain. All reported patients with sorafenib-associated RRD were male, with a median age of 51 years and an average daily sorafenib dose of 575 mg (range 300-800 mg). Symptoms started early after initiation of sorafenib, within 1-2 weeks.
The leading symptoms in the reported cases include erythematous skin lesions localized to areas of previous radiation exposure, marked by disseminated exanthematous rash, pruritus, and pain. RRD caused by other chemotherapeutics frequently occurred with an interval between radiotherapy and chemotherapy of less than 2 months [26] . Dose reduction or discontinuation of sorafenib together with systemic steroid therapy, antihistamines, and local treatment led to rapid improvement of symptoms. Rechallenge with the agent did not lead to recurrence of RRD.
There seems to be a radiation dose dependence of the severity of RRD. In contrast to other case reports with RRD after initiation of sorafenib, our patient was irradiated at several different locations with different radiation doses. He developed pronounced RRD in areas of the skin irradiated with a minimum of 30 Gy equivalent skin dose ( Table 1) . In particular, lesions near to the body surface and those irradiated with 3D-conformal radiotherapy are associated with high skin doses and are therefore more prone to RRD. Radiation-dose-dependent RRD has also been reported after treatment with bleomycin and docetaxel [27, 28] . Interestingly, the first occurrence of RRD in our patient was on the right upper arm, where he had received postoperative radiotherapy after osteosynthesis of a pathological humerus fracture. The RRD might have been triggered by the postoperative inflammatory environment. Other authors have hypothesized that potential triggers might be impaired epithelial function induced by the radiation effect on epithelial stem cells, changes in vascularization, or DNA repair [29] .
Sorafenib is an inhibitor of multiple intracellular and cell surface kinases. It blocks Raf kinases which mediate cell proliferation and differentiation, and inhibits angiogenesis, including inhibition of vascular endothelial growth factor receptor [30] . Generally, the pathogenetic process of RRD is controversial-ranging from an idiosyncratic hypersensitivity reaction, to a defect in DNA repair and a direct toxic effect of the respective agent [31] . Skin biopsy in our patient, which was not performed in previous reports of RRD caused by sorafenib, demonstrated vacuolization of the dermoepidermal junction, and apoptotic keratinocytes with sparse perivascular infiltrate of lymphocytes and eosinophils (Fig. 2) . The histological picture mimicked the pattern of graft-versus-host reactions of the skin or cutaneous drug allergies. An immune-mediated mechanism in the Fig. 1 Correlation of radiation recall dermatitis (right humerus, left scapula, T10) and acute radiation dermatitis (L1) with radiation fields irradiated area [32] . In addition to augmentation of an acute skin reaction, sorafenib might also enhance acute mucosal toxicity. Our patient displayed enhanced mucosal toxicity in the oral cavity (maximum biologically effective dose, BED 30 Gy; α/β = 8) and the urethra/bladder neck (maximum BED 9 Gy; α/β = 8) with urinary retention in response to radiotherapy of the mandible and the pelvic region, which might be related to the radiosensitizing effect of sorafenib described above.
RRD is more commonly reported with conventional chemotherapeutic agents, including the anthracycline doxorubicin, the taxanes docetaxel and paclitaxel, and the antimetabolites gemcitabine and capecitabine [1] . However, RRD has also been described with other targeted cancer therapies in case reports or case series, such as for the BRAF inhibitor vemurafenib [33, 34] , the EGFR inhibitor erlotinib [35] , and the multitargeting tyrosine kinase inhibitor sunitinib [25] . The BED ranged from 20 to 57 Gy, the interval between irradiation and targeted therapy from 1 to 1584 weeks, and the time to onset of RRD after targeted therapy start from 1 day to 87 weeks [36] . A clear correlation between the severity of RRD caused by sorafenib and the time interval between irradiation and the onset of symptoms (range 37-59 days) could not be demonstrated on the basis of our data (Table 1) . However, the most severe RRD developed in the area of the first occurrence at the humerus, 10 days after start of sorafenib. present case might be plausible, with fluctuating fever as a systemic reaction after rechallenge with sorafenib. However, fever as an unspecific symptom is reported with an incidence of about 10 % in patients treated with sorafenib.
Radiation recall reactions followed by sorafenib might not only be confined to skin reactions: cardiotoxicitiy has also been described [32] . Following irradiation of lung cancer and start of sorafenib 5 months after radiotherapy, a female patient presented with edema in the basal and midanterior wall of the heart muscle matching to the previously [22] 
